These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1542299)

  • 1. Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse.
    Wawrzynczak EJ; Denham S; Parnell GD; Cumber AJ; Jones PT; Winter G
    Mol Immunol; 1992 Feb; 29(2):221-7. PubMed ID: 1542299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending human IgG half-life using structure-guided design.
    Booth BJ; Ramakrishnan B; Narayan K; Wollacott AM; Babcock GJ; Shriver Z; Viswanathan K
    MAbs; 2018 Oct; 10(7):1098-1110. PubMed ID: 29947573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of the binding site for the human high-affinity Fc receptor on IgG.
    Duncan AR; Woof JM; Partridge LJ; Burton DR; Winter G
    Nature; 1988 Apr; 332(6164):563-4. PubMed ID: 2965792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains.
    Wawrzynczak EJ; Cumber AJ; Parnell GD; Jones PT; Winter G
    Mol Immunol; 1992 Feb; 29(2):213-20. PubMed ID: 1542298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.
    Kelley RF; Meng YG
    Methods Mol Biol; 2012; 901():277-93. PubMed ID: 22723108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.
    Zwolak A; Armstrong AA; Tam SH; Pardinas JR; Goulet DR; Zheng S; Brosnan K; Emmell E; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017; 9(8):1306-1316. PubMed ID: 28898162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of a high-affinity binding site for the globular head regions of the C1q complement protein on a human diploid fibroblast subtype.
    Bordin S; Page RC
    Mol Immunol; 1989 Jul; 26(7):677-85. PubMed ID: 2789337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced elimination of IgG antibodies by engineering the variable region.
    Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
    Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG Fc engineering to modulate antibody effector functions.
    Wang X; Mathieu M; Brezski RJ
    Protein Cell; 2018 Jan; 9(1):63-73. PubMed ID: 28986820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
    Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.
    Fonseca MHG; Furtado GP; Bezerra MRL; Pontes LQ; Fernandes CFC
    Int J Biol Macromol; 2018 Nov; 119():306-311. PubMed ID: 30041038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to extend plasma half-lives of recombinant antibodies.
    Kontermann RE
    BioDrugs; 2009; 23(2):93-109. PubMed ID: 19489651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of platelet factors and serum complement in growth of fibroblasts with high-affinity Clq complement receptors.
    Bordin S; Page RC
    In Vitro Cell Dev Biol; 1988 Jul; 24(7):719-26. PubMed ID: 3294228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11.
    Lund J; Pound JD; Jones PT; Duncan AR; Bentley T; Goodall M; Levine BA; Jefferis R; Winter G
    Mol Immunol; 1992 Jan; 29(1):53-9. PubMed ID: 1530984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.